Search results | respiratory

Reports

Respiratory Partnering Terms and Agreements

The Respiratory Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies.

Respiratory Syncytial Virus Partnering

The RSV Partnering provides understanding and access to the RSV partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Orexo and J&J join forces to advance small molecule respiratory treatment programs

Orexo and J&J through its Ortho-McNeil-Janssen subsidiary have decided that bringing their respective expertise and compounds into a single R&D pool will serve both parties best interests when it comes to developing a new generation of drugs to treat asthma, COPD and other serious inflammatory diseases.

Merger news : Actavis eyes $3 billion bid for Almirall

Merger news: Rumors that Ireland-based Actavis  is still looking to buy up a company or two continue with speculation that it is considering Spanish drugmaker Almirall SA. Actavis, which is domiciled in Ireland, but operates out of Parsippany, N.J. was also earlier rumored to be interested in buying GI drugmaker Salix Pharmaceuticals and Omega Pharma NV.

Aspen Pharmacare – Africa’s biggest generic drugmaker

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Roche drops business merger rumors with Chugai Pharmaceutical

Roche had business merger rumors to buy Tokyo-based Chugai Pharmaceutical Co., Ltd. appear to be tabled for now. Sources in Roche indicated the company was focused on its $8.3 billion acquisition of California-based InterMune Inc.

Current Agreements Deal Analysis Update : August 2014

This month we provide you with a deal analysis  overview of life science partnering, M&A and financing in July 2014.

SciClone Pharmaceuticals: Big biotech partnering trends 2009-2014

SciClone Pharmaceuticals is a US based specialty company. The company focusses its efforts to widen its portfolio in China by in-licensing and acquiring rights to marketed products.

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Sun Pharmaceutical: Fast becoming the branded generic company of choice

Sun Pharmaceutical is a global specialty pharmaceutical company serving over 40 different markets with its brands and branded generics.

Takeda Pharmaceuticals

Takeda Pharmaceuticals is a top pharmaceutical company based in Osaka, Japan

Events

Sorry, your search returned no results.


Deals

AstraZeneca enters asset purchase deal for branded respiratory portfolio

AstraZeneca and Actavis have entered into a definitive asset purchase agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of

AstraZeneca acquires Almirall’s respiratory business

AstraZeneca has entered an agreement to acquire the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion.

Respiratory R&D collaboration announced for Stallergenes and DBV Technologies

Stallergenes S.A. (Paris:GENP), worldwide leader in allergen immunotherapy, and DBV Technologies (Euronext Paris: DBV), creator of Viaskin(R) for the treatment of allergies, announced today that they have entered into a research and development agreement for the treatment of birch allergy.

Mylan to buy respiratory products from Pfizer for $17.5 million

Mylan has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer’s generic equivalent to GlaxoSmithKline’s Advair Diskus and Seretide Diskus incorporating Pfizer’s proprietary dry powder inhaler delivery platform. 

Teva aims to add $2.4bn to respiratory franchise

As usual, Teva Pharmaceutical Industries has big plans.

Crucell N.V. reaches agreement with Sanofi Pasteur on programs in the field of paediatric and respiratory vaccines

Dutch biopharmaceutical company Crucell N.V, today announced that Crucell and sanofi pasteur reached an agreement on a series of transactions to restructure their long standing partnership.

Orexo signs respiratory disease pact with Johnson & Johnson

The agreement gives J&J units Ortho-McNeil-Janssen Pharmaceuticals and Janssen Pharmaceutica licenses to two of Orexo’s advanced preclinical programmes focusing on discovering and developing small-molecule treatments for asthma, chronic obstructive pulmonary disease and other inflammatory diseases

Almirall and Forest to expand respiratory collaboration with LAS100977

Agreement to develop, market and distribute LAS100977 in the United States. LAS100977 is an inhaled, once-daily administered long-acting beta2 agonist (LABA) that until now has been developed by Almirall to treat bronchoconstriction in asthmatic patients.

Novartis assumes rights to Schering-Plough respiratory drug

Novartis has assumed worldwide rights to a combination respiratory medicine it was developing with Schering-Plough.

BioDuro and AstraZeneca expand collaboration to optimize discovery research for respiratory and inflammation

BioDuro will provide integrated research services in the areas of discovery chemistry, discovery biology, ADMET*, and DMPK** services, to help enhance internal drug discovery and shorten development timelines.